Generated by AI
Grifols S.A. ADR is a healthcare and biotechnology asset representing Grifols’ U.S. depositary shares. Grifols is a global specialty plasma therapeutics company focused on the research, development, manufacturing, and distribution of plasma-derived medicines and related biopharmaceutical products. Its core activities span biopharma, diagnostic solutions, bio supplies, and other healthcare services, supporting treatment areas such as immunodeficiencies, bleeding disorders, and hospital-based care. The company also provides diagnostic systems, reagents, and products used in transfusion medicine and clinical laboratories, making it an important supplier to hospitals, blood centers, and healthcare providers. Grifols S.A. ADR gives investors access to a multinational healthcare business whose products and services are deeply embedded in the plasma medicine and diagnostics market.
WebsiteParque Empresarial Can Sant Joan
Barcelona, 08174
Spain
The latest articles about GRFS.
Motley Fool Press Release.
Summary of Jul 23's posts. Generated by AI.
Summary of Jul 23's posts. Generated by AI.
Summary of Jul 23's posts. Generated by AI.
Investors talking about GRFS also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.